Article

Research and Development of a Multi-Target HER2 Inhibitor (CPD 1) and Its Mechanism and Application in Combating HER2-Positive Breast Cancer

2026-04-03

Abstract excerpt

<title>Abstract</title> <p>HER2-positive breast cancer, particularly in patients with central nervous system metastasis, presents significant clinical challenges due to limited treatment options and extremely poor prognosis. This paper reports the rational design, synthesis, and systematic evaluation of a novel multi-target HER2 inhibitor, CPD 1. Employing a ‘skeletal leap-pharmacophore retention-multi-mechanism...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7863c97-5d1b-529d-a9e3-d47f3b294a12
DOI: 10.21203/rs.3.rs-9021276/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Research and Development of a Multi-Target HER2 Inhibitor (CPD 1) and Its Mechanism and Application in Combating HER2-Positive Breast CancerDOI 10.21203/rs.3.rs-9021276/v1Read

Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insightsSemantic proximity Read

Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological TargetsSemantic proximity Read

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapiesSemantic proximity Read

A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategySemantic proximity Read

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read

EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastomaSemantic proximity Read

Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer.Semantic proximity Read

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignSemantic proximity Read

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activitySemantic proximity Read

A Bptf Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Triple Negative Breast Cancer Cells to ChemotherapySemantic proximity Read

Metallodrugs: an approach against invasion and metastasis in cancer treatmentSemantic proximity Read